HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation by Cenderello, G. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ierp20
Expert Review of Pharmacoeconomics & Outcomes
Research
ISSN: 1473-7167 (Print) 1744-8379 (Online) Journal homepage: http://www.tandfonline.com/loi/ierp20
HCV elimination plan leads to significant benefits
in managing liver-related diseases and hospital
interventions: a regional simulation
Giovanni Cenderello, Lucia Taramasso, Domenico Marra, Patrizia Orcamo,
Ambra Pasa & Antonio Di Biagioon behalf of HIV/HCV Collaborative Liguria
Group
To cite this article: Giovanni Cenderello, Lucia Taramasso, Domenico Marra, Patrizia Orcamo,
Ambra Pasa & Antonio Di Biagioon behalf of HIV/HCV Collaborative Liguria Group (2018): HCV
elimination plan leads to significant benefits in managing liver-related diseases and hospital
interventions: a regional simulation, Expert Review of Pharmacoeconomics & Outcomes Research,
DOI: 10.1080/14737167.2019.1537124
To link to this article:  https://doi.org/10.1080/14737167.2019.1537124
Accepted author version posted online: 15
Oct 2018.











Publisher: Taylor & Francis 
Journal: Expert Review of Pharmacoeconomics & Outcomes Research 
DOI: 10.1080/14737167.2019.1537124 
Original Research 
HCV elimination plan leads to significant benefits in managing liver-related diseases 
and hospital interventions: a regional simulation 
Giovanni Cenderello*1, Lucia Taramasso2,3, Domenico Marra4, Patrizia Orcamo5, Ambra Pasa6, Antonio Di Biagio7 
on behalf of HIV/HCV Collaborative Liguria Group§. 
1. Infectious Diseases Unit, EO Ospedali Galliera, Genoa Italy, giovanni.cenderello@galliera.it. 
2. Infectious Diseases Unit, Hospital Policlinico San Martino, Department of Health Science (DISSAL), 
University of Genoa, Genoa. Italy, taramasso.lucia@gmail.com. 
3. Infectious Diseases Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore 
Policlinico, Milan, Italy 
4. Oncology Unit, EO Ospedali Galliera, Genoa Italy, domenico.marra@galliera.it. 
5. Regione Liguria, Department Health and Social Care. Health promoting unit, Genoa,Italy, 
patrizia.orcamo@regione.liguria.it. 
6. IT Unit, EO Ospedali Galliera, Genoa, Italy, ambra.pasa@galliera.it. 
7. Infectious Diseases Unit, Hospital Policlinico San Martino, Genoa, Italy, antonio.dibiagio@hsanmartino.it. 
 
*Corresponding Author: 
Dott. Giovanni Cenderello,  
Infectious Diseases Unit EO Ospedali Galliera,  
Via Volta 8, 16128 Genoa, Italy 
Mail: giovanni.cenderello@galliera.it 
Telehon number: +39 010 563 4472  











Objectives: This article presents a 3-year budget impact simulation on the effects of a chronic Hepatitis C (HCV) eradication plan in real-life costs incurred by the Regional Health Service in the Liguria Region (in Northern Italy).  
Methods: The Liguria Region network performed a prospective 3-year (2017–2019) timeframe horizon trends simulation analysis focusing on management interventions and costs. It involved all the eight prescribing centres in the region, starting from retrospective historical performance data and assuming impact of sustained viral response rates for patients treated for HCV. Data on hospital admissions, medical visits, number of patients and deaths were collected through the healthcare database. 
Results: At the beginning of 2017, 2,940 patients were eligible for HCV treatment with direct-acting antivirals. Assuming to treat this entire population with a success rate of 90%, the events related to liver complications in the 3-year horizon would decrease to 5,538 cumulatively (-35%), with a 27% reduction of direct costs, showing a global savings of 24,779.024 Euros. 
Conclusion: Treating the entire eligible HCV population would lead to significant benefits and savings in managing liver-related diseases and their direct costs, opening opportunities to re-think new settings for the future organisation of liver disease management in the regional health system. 
 














1. Introduction Chronic hepatitis C has affected about 200 million people around the world. The recent advances in treating such a severe disease show a dramatic change in morbidity and mortality related to HCV. Accordingly, not only patients’ perspectives have changed radically but also the improvements have had such an effective impact that the global eradication of HCV has been introduced in the “wish list” of the World Health Organisation (1).  The most recent treatment schedules are offering a sustained virological response (SVR) in about 90% of patients in only 8 weeks of treatment, with a minimal impact on patients’ quality of life. The goal of antiviral treatment is to reduce the onset of disease complications, including liver cirrhosis and hepatocellular carcinoma. Starting from their introduction in 2014, the new wave of direct-acting antiviral (DAA) regimens have provided dramatic improvements in clinical outcomes, surpassing a 90% SVR (2,3). As of June 2017, the following DAA regimens are available and reimbursable in Italy: (sofosbuvir/velpatasvir, ombitasvir/paritaprevir/ritonavir and dasabuvir, /elbasvir/grazoprevir).  Several economic analyses have evaluated the impact of the HCV patient journey in different Italian settings (4,5). However, up to now, no studies had investigated the potential effects on overall liver-related resources that the clinical utilisation of a new generation of DAAs will have on the HCV national elimination plan supported by the National Health System (NHS) innovative drug fund (€ 500 million/year for 2017, 2018 and 2019). This paper aims to estimate the impact and consequences of treating HCV in managing liver diseases and other liver-related direct costs. 
 
2. Methods 









To reach the main objective, we initially performed a retrospective analysis concerning liver-related patient management interventions and their costs during the 2014–2016 timeframe across the Liguria Region network, involving the eight prescribing centres.  Figures (data/numbers/facts) on hospital admissions, medical visits, number of patients and deaths were collected through the healthcare database (6). Subsequently a prospective 3-year horizon trends simulation analysis was conducted on the same services and cost lists; the study was approved by the Liguria Region Local Ethical Committee (approval ID 268REG2016). All patients eligible for therapy, according to the new Italian Drug Agency (AIFA) criteria (2,940 people – Table 1), were enrolled. For the prospective analysis, we assumed SVR rates not inferior to the ones obtained in real clinical practice (7). Since the NHS special funds cover 100% of the drug supply, DAA costs were excluded, and we focused on the consequences of other liver-related direct costs. 
2.2 Data sources 
 Data was analysed from the point of view of the Regional Health Service (RHS). Treatment costs included outpatient services, attended visits and inpatient service admissions. Hospitalisation was classified using ICD-9 codes, and the financial costs considered were calculated from the Italian NHS rate table. According to the AIFA, DAAs are fully reimbursable for all fibrosis stages, therefore providing complete coverage of the entire eligible population (8). The criteria defined by the AIFA have been summarised in Table 2. 
 









and the related direct costs. SVR rates varied over a range of 2–5%, assuming a high performance of success as demonstrated in several studies (7). 
 
3. Results 
3.1 Population During the 2014–2016 period, 8,464 patients were assisted for liver-related complications (Table 2). At the beginning of 2017, 2,940 people were eligible for HCV treatment with DAAs. By assuming to treat this population with a cure success rate of > 90%, the patients assisted due to liver-related complications in the 3-year horizon should decrease to 5,538 patients  (-35%). This reduction is remarkably higher among the less severely affected population (no cirrhosis or hepatocellular carcinoma (HCC), -89%. 
 
3.2 Hospitalisation and day hospital care A detailed analysis of hospitalisation (Table 3) showed a significant reduction in the number of activities. Overall, inpatient visits declined from 10,683 (2014–2016 period) to 6,830 (2017–2019 period), -36%, with a greater reduction in hospitalisation and a stronger focus on the less complicated cases (-89%). Days of hospitalisation declined from 87,514 to 65,725,  (-25%); a similar trend was noticed on day hospital admissions, declining from 17,603 to 5,033 accesses (-71%), with a peak of -97% for patients with less severe conditions. 
 
3.3 Deaths Another major consequence of treating people for HCV resulted in an overall -21% of deaths among liver-related disease conditions (846 vs 1,077).  


















analyses together tend to suggest that treating HCV will also help to decrease liver management economic expenses and, at the same time, allow us to concentrate more efforts on the most complex and severe cases. Sensitivity analysis (Table 5) confirms the SVR rate as the major contributor to the total cost. Excluding anti-HCV treatment costs, as we assumed an “ad-hoc” budget for them, an increase in SVR rate led to a major reduction in overall costs. 
 
4. Discussion The use of DAA therapies is reducing the burden of HCV disease in Italy. As of early August 2017, more than 86,000 patients have already been treated. Ad-hoc funds for the innovative drugs (DAAs are included in this list) will facilitate treating patients with less stress on the regional healthcare resources. New generation DAAs will further improve the SVR rates. Several studies demonstrated that DAA regimens (9) such as sofosbuvir/velpatasvir are 
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Table 1. Patients eligible for HCV treatment at 1 April 2017 (source DB-Rete Ligure  HIV/HCV)  















Table 2. AIFA (Italian Agency for Drugs) Criteria for prescription/reimbursement of 
DAAs in Italy.  Criteria  Description Criteria 1 Patients affected by liver cirrhosis (Child A or B) and/or Hepatocellular carcinoma already treated. Criteria 2 HCV reinfection (HCV RNA positive) in clinically stable patients after liver transplantation and with excellent levels of immunosuppression Criteria 3 Chronic hepatitis C with severe extra hepatic manifestations (e.gh. kidney failure, lymphoproliferative diseases, cryoglobulinemic syndrome) with organ damage Criteria 4 Chronic Hepatitis C with METAVIR F3 stage   Criteria 5 Patients on liver transplantation list affected by liver cirrhosis MELD score<25 within the Milano criteria with at least a two-months waiting list Criteria 6 Chronic Hepatitis after solid organ (not liver) or bone marrow transplantation on clinically stable patients and with optimum levels of immunosuppression Criteria 7 Chronic Hepatitis with fibrosis METAVIR F 2 and/or other diseases at risk of worsening liver disease [coinfection HBV, HIV, chronic 
non-viral liver diseases, patients with diabetes 
mellitus in treatment, obesity (body mass 
index ≥30 kg/m2), haemoglobinopathies and 
congenital coagulopathy]. Criteria 8 Chronic Hepatitis with fibrosis METAVIR F 0-F1 and/or other diseases at risk of worsening liver disease [coinfection HBV, HIV, chronic 
non-viral liver disease, patients with diabetes 
mellitus in treatment, obesity (body mass 
index ≥30 kg/m2), haemoglobinopathies and 




















Table 3 -  Liver-related direct interventions and health resource consumption. 
Historical Trends Expected Trends 
  Year Year Year Total Total Diff  (%)









2.301 8.464 5.538 -35%202 Liver cirrhosis and alcoholic hepatitis 946 973 702 2.621 1.745 -33%203 Hepatobiliary / pancreas tumors (HCC) 1.236 1.198 1.029 3.463 2.861 -17%205 Liver disease no neoplasms/cirrhosis -  complicated 453 417 307 1.177 796 -32%206 Liver disease no neoplasms/cirrhosis  - not complicated 537 403 263 1.203 136 -89%






2.915 10.683 6.838 -36%202 Liver cirrhosis and alcoholic hepatitis 1.338 1.342 987 3.667 2.255 -39%203 Hepatobiliary / pancreas tumors (HCC) 1.644 1.537 1.320 4.501 3.643 -19%205 Liver disease no neoplasms/cirrhosis -  complicated 484 450 333 1.267 809 -36%206 Liver disease no neoplasms/cirrhosis  - not complicated 559 414 275 1.248 131 -89%






26.281 87.514 65.725 -25%202 Liver cirrhosis and alcoholic hepatitis 11.145 10.200 9.641 30.986 21.533 -31%203 Hepatobiliary / pancreas tumors (HCC) 14.636 13.013 11.760 39.409 32.938 -16%205 Liver disease no neoplasms/cirrhosis -  complicated 4.327 4.082 3.233 11.642 7.910 -32%206 Liver disease no neoplasms/cirrhosis  - not complicated 2.115 1.715 1.647 5.477 3.344 -39%
















































Table 4a: Overall mean cost per patient/DRG 
DRG code Clinical category 2014-16 (years) 2017-19 (years) Diff ( %) 202 Liver cirrhosis and alcoholic hepatitis 4.758,69 4.440,45 -7% 203 Hepatobiliary / pancreas tumors (HCC) 4.495,97 4.980,94 11% 205 Liver disease no neoplasms/cirrhosis -  complicated 3.643,66 3.381,50 -7% 206 Liver disease no neoplasms/cirrhosis  - not complicated 1,457.48 652,04 -55% All Mean costs (€) 4,026.94 4.474,69 11% 
Abbreviation: DRG, diagnosis related group. 
  
Table 4b: Mean weigthing by DRG 
Description 2014-16 (years) 2017-19 (years) Diff ( %) 
Patients (n.) 8,464 5.538 -35% 
Hospitalizations cases (n.) 1,22 1,26 3,7% 
Hospitalizations days  1,24 1,25 0,6% 
Day hospital activities (n.) 1,20 1,27 5,7% 
Deaths (n.) 1,077 846 -21,4% 
Expenditure (€) 34,083.988 24,779.024 -27% 
 











Table5 Cost (in €) and sensitivity analysis. Table is simulating the total cost variations at the 
change of SVR rate (% is indicating the SVR rate change) 
 
Variable   Liver disease direct costs 
Baseline      24,779.024  
SVR (%) 
−2      25,320.538  
−5      25,617.959  
+2     24,260.652  
+5      23,522.177  
 
 
 
